HELEN EDE: Open Payments
NPI 1265536759 · MADISON, CT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,901 in 93 payments from 16 companies in 2025. Trend: 2023 $2,165 · 2024 $1,792 · 2025 $1,901
Food & beverage: $1,841Education: $60
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 26 | $456 |
| Astellas Pharma US Inc | 9 | $224 |
| Vanda Pharmaceuticals Inc. | 7 | $208 |
| Lilly USA, LLC | 8 | $193 |
| GlaxoSmithKline, LLC. | 12 | $185 |
| Novo Nordisk Inc | 9 | $176 |
| Otsuka America Pharmaceutical, Inc. | 5 | $112 |
| AstraZeneca Pharmaceuticals LP | 4 | $82 |
| Amgen Inc. | 4 | $73 |
| PFIZER INC. | 3 | $67 |
Products named: VRAYLAR, FANAPT, MOUNJARO, Veozah, TRELEGY ELLIPTA, REXULTI, UBRELVY, OTEZLA.
Industry payments across CT — which companies pay providers there.
